DCTH

Delcath Systems Inc

Add to Watchlist

Advanced Chart

14.840

+0.485(+3.380%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

15.980

Open

14.370

VWAP

15.46

Vol

940.93K

Mkt Cap

516.82M

Low

14.370

Amount

14.55M

EV/EBITDA(TTM)

Total Shares

27.79M

457.92M

EV/OCF(TTM)

P/S(TTM)

9.11

Delcath Systems, Inc. is an interventional oncology company. The Company is focused on the treatment of primary and metastatic liver cancers. The Company’s proprietary products, HEPZATO Kit (melphalan hydrochloride for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATO Kit is comprised of the chemotherapeutic drug melphalan and Delcath’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is sold under the trade name CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT), where it has been used in the conduct of percutaneous hepatic perfusion procedures at medical centers to treat a range of cancers of the liver.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

28.18M

+86.64%

24.89M

+122.21%

21.68M

+179.15%

Estimates Revision

The market is revising Upward the revenue expectations for Delcath Systems, Inc. (DCTH) for FY2025, with the revenue forecasts being adjusted by 20.24% over the past three months. During the same period, the stock price has changed by -7.08%.

Revenue Estimates for FY2025

Revise Upward

+20.24%

In Past 3 Month

Stock Price

Go Down

-7.08%

In Past 3 Month

4 Analyst Rating

50.47% Upside

Wall Street analysts forecast DCTH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DCTH is 22.33 USD with a low forecast of 21.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

50.47% Upside

Current: 14.840

Low

21.00

Averages

22.33

High

24.00

50.47% Upside

Current: 14.840

Low

21.00

Averages

22.33

High

24.00

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Maintains

$22 → $24

2025-03-07

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

$22 → $24

2025-03-07

Maintains

Strong Buy

Reason

Craig-Hallum

Chase Knickerbocker

Strong Buy

Maintains

$18 → $21

2025-01-17

Reason

Craig-Hallum

Chase Knickerbocker

Price Target

$18 → $21

2025-01-17

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Reiterates

$22

2025-01-14

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

$22

2025-01-14

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Reiterates

$22

2024-11-11

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

$22

2024-11-11

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Reiterates

$22

2024-10-18

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

$22

2024-10-18

Reiterates

Strong Buy

Reason

Canaccord Genuity

John Newman

Strong Buy

Maintains

$21

2024-10-18

Reason

Canaccord Genuity

John Newman

Price Target

$21

2024-10-18

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Delcath Systems Inc (DCTH.O) is 109.93, compared to its 5-year average forward P/E of -15.54. For a more detailed relative valuation and DCF analysis to assess Delcath Systems Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-15.54

Current PE

109.93

Overvalued PE

34.27

Undervalued PE

-65.35

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-7.50

Current EV/EBITDA

11.60

Overvalued EV/EBITDA

20.11

Undervalued EV/EBITDA

-35.12

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

16.69

Current PS

4.58

Overvalued PS

32.42

Undervalued PS

0.95

Financials

Annual

Quarterly

FY2025Q1

YoY :

+530.26%

19.78M

Total Revenue

FY2025Q1

YoY :

-106.25%

642.00K

Operating Profit

FY2025Q1

YoY :

-100.00%

N/A

Net Income after Tax

FY2025Q1

YoY :

-106.67%

0.03

EPS - Diluted

FY2025Q1

YoY :

-121.50%

2.06M

Free Cash Flow

FY2025Q1

YoY :

+20.20%

85.62

Gross Profit Margin - %

FY2025Q1

YoY :

-98.23%

-14.08

FCF Margin - %

FY2025Q1

YoY :

-101.53%

5.40

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 591.65% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

1.6M

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

DCTH News & Events

Events Timeline

2025-05-08 (ET)

2025-05-08

07:51:52

Delcath Systems reports Q1 EPS 3c, consensus 3c

2025-04-28 (ET)

2025-04-28

08:36:07

Delcath Systems announces FDA clearance of IND application for Hepzato trial

2025-03-06 (ET)

2025-03-06

08:12:17

Delcath Systems reports Q4 EPS (11c), consensus 1c

News

5.0

05-09Newsfilter

Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

9.5

05-08SeekingAlpha

Delcath Systems GAAP EPS of $0.03 beats by $0.02, revenue of $19.78M beats by $2.95M

2.0

04-28Benzinga

Eagle Financial Services, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session

People Also Watch

YMAB

Y-mAbs Therapeutics Inc

Proficient Auto Logistics Inc

Smart Share Global Ltd

OraSure Technologies Inc

Gran Tierra Energy Inc

4.530

USD

+2.95%

FAQ

What is Delcath Systems Inc (DCTH) stock price today?

The current price of DCTH is 14.84 USD — it has increased 3.38 % in the last trading day.

DCTH

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

DCTH News & Events

Events Timeline

News

People Also Watch

FAQ

What is Delcath Systems Inc (DCTH) stock price today?

What is Delcath Systems Inc (DCTH)'s business?

What is the price predicton of DCTH Stock?

What is Delcath Systems Inc (DCTH)'s revenue for the last quarter?

What is Delcath Systems Inc (DCTH)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Delcath Systems Inc (DCTH)'s fundamentals?

How many employees does Delcath Systems Inc (DCTH). have?

What is Delcath Systems Inc (DCTH) market cap?